What one share of Immunic holds
Immunic, Inc. (“Immunic," “we,” “us,” “our” or the "Company") is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. We are headquartered in New York City with our main operations in Gräfelfing near Munich, Germany.
Immunic’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.01 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.17 |
| Dividends | $0.00 |
| Cash and investments | $11.37 |
| Book value | $9.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | — | −$1,770 | $43.88 | −$1,315 | — | $2,034 |
| 2015 | — | −$1,034 | $46.52 | −$1,039 | — | $1,351 |
| 2016 | — | −$652.63 | $8.86 | −$578.73 | — | $909.14 |
| 2017 | — | −$653.28 | $8.59 | −$515.34 | — | −$157.39 |
| 2018 | — | −$136.28 | $0.38 | −$115.35 | $0.00 | −$303.92 |
| 2019 | — | −$45.24 | $0.07 | −$37.04 | $0.00 | $54.32 |
| 2020 | — | −$28.10 | $0.09 | −$29.54 | $0.00 | $75.01 |
| 2021 | — | −$39.30 | $0.03 | −$35.22 | $0.00 | $48.27 |
| 2022 | — | −$37.84 | $0.04 | −$20.51 | $0.00 | $28.92 |
| 2023 | — | −$21.12 | $0.08 | −$16.06 | $0.00 | $6.40 |
| 2024 | — | −$10.03 | $0.03 | −$8.49 | $0.00 | $2.04 |
| 2025 | — | −$6.24 | $0.01 | −$5.52 | $0.00 | −$0.74 |
Common questions about Immunic
How much does one share of Immunic earn?
Over the last 12 months, Immunic lost $4.01 for each share.
Does Immunic pay a dividend?
Immunic didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Immunic’s book value per share?
Immunic’s book value is $9.35 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Immunic have?
Each share of Immunic has $11.37 of cash and investments, as of June 30, 2026.
What is Immunic’s free cash flow per share?
−$3.17 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Immunic bought back shares?
Immunic’s share count rose about 48387% from 2014 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.